To observe the clinical efficacy of low-dose spironolactone in the treatment of advanced coronary heart disease (CAD) with chronic heart failure (CHF).

A total of 84 patients with CAD and CHF admitted to Dancheng People's Hospital from September of 2016 to June of 2017 were included in the study. They were divided into two groups according to the random number table method, 42 cases in each group. Patients in group A received routine treatment, while patients in group B received low-dose spironolactone adjuvant therapy on the basis of routine treatment. The total effective rate, the level of LVEF, NT-proBNP before and after treatment and the incidence of adverse reactions were compared between the two groups.

The total effective rate of group A was 78.57% and that of group B was 95.24%. The total effective rate of group B was higher than that of group A, and the difference was statistically significant (P<0.05). After treatment, the level of LVEF in group B was higher than that in group A (P<0.05), and the level of NT-proBNP was lower than that in group A (P<0.05). The incidence of adverse reactions was 9.52% in group A and 11.90% in group B. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Low-dose spironolactone has a good clinical efficacy in the adjuvant treatment of CAD combined with CHF, which can effectively improve the cardiac function of patients, and does not increase the risk of drug use, so it can be popularized in clinic.